19:49:24 EDT Wed 18 Sep 2019
Enter Symbol
or Name

Emerald Health Therapeutics Inc
Symbol C : EMH
Shares Issued 142,645,495
Close 2019-03-11 C$ 3.89
Recent Sedar Documents

ORIGINAL: Emerald Health JV receives 7th amendment to pot licence

2019-03-11 09:43 ET - News Release

Received by email:

File: Emerald Health Therapeutics Sees Pure Sunfarms Licensed for 1.03Million Square Feet of Cannabis Cultivation; Full 
--->Planting Targeted for Endof April.pdf

Emerald Health Therapeutics Sees Pure Sunfarms Licensed for 1.03 Million Square Feet of Cannabis
Cultivation; Full Planting Targeted for End of April
March 11, 2019
  Pure Sunfarms' large-scale facility with 16 grow rooms is optimized for year-round production and expected to yield
                                              more than 80 harvests annually

VICTORIA, British Columbia, March 11, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. ("Emerald") (TSXV:EMH; 
today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfa
--->rms Corp. ("Pure Sunfarms"),
received from Health Canada its seventh amendment to its cultivation license for its 1.1 million square foot greenhouse 
--->in Delta, BC. The additional
approximately 206,000 square feet of growing area in the fourth and final quadrant of the greenhouse brings Pure Sunfarm
--->s' total licensed cannabis
production area to approximately 1.03 million sq. ft. in 16 grow rooms. The newly licensed area is expected to be fully 
--->planted by the end of March.

"Pure Sunfarms is now licensed across all its growing areas and we congratulate their team for this significant accompli
--->shment," said Dr. Avtar Dhillon,
President and Executive Chairman of Emerald. "With Emerald's 50% stake in one of the largest fully operational cannabis 
--->production facilities in the
world, we expect to realize significant economic value from Pure Sunfarms. We expect our supply agreement with Pure Sunf
--->arms for 40% of its 2019
production, along with our Quebec and hemp operations, to support strong quarter to quarter sales growth this year."

Pure Sunfarms is now replanting Quadrant 1 of the greenhouse following the planned suspension of production in that area
---> last autumn to begin the
process of installing supplemental lighting to maximize yields in the winter months. This project is planned to be compl
--->eted in Q3, when supplemental
lighting will again be required. Pure Sunfarms expects Quadrant 1 to be fully replanted by the end of April 2019, at whi
--->ch time Pure Sunfarms will be in
production in the entire 1.03 million square feet of cultivation space.

Last week, Pure Sunfarms announced a wholesale supply agreement with Canna Farms Ltd., which will offer a select variety
---> of Pure Sunfarms-
branded high-quality dried flower products to Canna Farms' medical clients for retail purchase. This initiative is inten
--->ded to help expand the marketing
and sales reach of Pure Sunfarms' branded products.

About Emerald Health Therapeutics, Inc.

Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture
---> in BC has a 1.1 million
square foot (25 acre) greenhouse with 1.03 million square feet of licensed cannabis cultivation space in Delta, BC. Its 
--->Verdelite operation in Quebec is
completing the build-out of its 88,000 square foot indoor cultivation facility. Commercial production is expanding in bo
--->th facilities. Emerald secured
over 500 acres of hemp harvest in 2018 and expects to purchase approximately 1,000 acres in 2019 to 2022, with the objec
--->tive of extracting low-cost
cannabidiol (CBD). Emerald's team is highly experienced in life sciences, product development, large-scale agri-business
--->, and marketing, and is
focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of
---> the Emerald Health group,
which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products 
--->developed to provide
wellness and medical benefits by interacting with the human body's endocannabinoid system.

Please visit http://www.emeraldhealth.ca for more information or contact:

Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5

Investor Relations
(800) 757 3536 Ext. #5

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TS
--->X Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not histori
--->cal facts are forward-
looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which g
--->ive rise to the possibility that
actual results or events could differ materially from our expectations expressed in or implied by such forward-looking s
--->tatements. Such statements
include planting schedules; future sales; realization of economic value; build out of the Verdelite facility; production
---> capacity of various facilities; and
receipt of hemp deliveries.

Actual results may vary from forward-looking statements. We cannot guarantee that any forward-looking statement will mat
--->erialize, and readers are
cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risk
--->s and uncertainties related
to, among other things, results of production and sale activities; results of scientific research; regulatory changes; c
--->hanges in prices and costs of
inputs; demand for labour; demand for products; future distribution agreements; failure of counterparties to perform con
--->tractual obligations; as well as
the risk factors described in the Company's annual information form and other regulatory filings. The forward-looking st
--->atements contained in this
press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose
---> of providing information
about management's current expectations and plans and allowing investors and others to obtain a better understanding of 
--->our anticipated operating
environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertak
--->es no obligations to
update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by 
--->applicable law.
 Source: Emerald Health Therapeutics Inc.

© 2019 Canjex Publishing Ltd. All rights reserved.